Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication

PeerJ

Volumn 2019, Issue 2, 2019, Pages

  Weiss, Glen J ^a,b   Davis, Roger B ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Discordance; Financial conflicts of interest; Oncology; Publication

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CONFLICT OF INTEREST; FINANCIAL INFORMATION SYSTEM; HUMAN; PREVALENCE; PUBLICATION; SCIENTIFIC LITERATURE; SOLID MALIGNANT NEOPLASM;

EID: 85063662654     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.6423     Document Type: Article

References (14)

1. Daly B, Bach PB, Page RD. 2018. Financial conflicts of interest among oncology clinical pathway vendors. JAMA Oncology 4(2):255-257 DOI 10.1001/jamaoncol.2017.4473.
2. Hampson LA, Joffe S, Fowler R, Verter J, Emanuel EJ. 2007. Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25(24):3609-3614 DOI 10.1200/JCO.2006.09.3633.
3. Hayes MJ, Prasad V. 2018. Financial conflicts of interest at FDA drug advisory committee meetings. Hastings Center Report 48(2):10-13 DOI 10.1002/hast.833
4. Jang S, Chae YK, Majhail NS. 2011. Financial conflicts of interest in economic analyses in oncology. American Journal of Clinical Oncology 34(5):524-528 DOI 10.1097/COC.0b013e3181f4799b.
5. Johnston KL, Go RS. 2007. Financial conflicts of interest among ASCO annual meeting abstract authors, speakers, and planners. JNCI Journal of the National Cancer Institute 99(18):1415-1416 DOI 10.1093/jnci/djm108.
6. Kaestner V, Prasad V. 2017. Financial conflicts of interest among editorialists in high-impact journals. Blood Cancer Journal 7(9):e611 DOI 10.1038/bcj.2017.92.
7. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. 2006. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. JAMA 295(16):1921 DOI 10.1001/jama.295.16.1921.
8. Mitchell AP, Basch EM, Dusetzina SB. 2016. Financial relationships with industry among national comprehensive cancer network guideline authors. JAMA Oncology 2(12):1628-1631 DOI 10.1001/jamaoncol.2016.2710.
9. Shawwa K, Kallas R, Koujanian S, Agarwal A, Neumann I, Alexander P, Tikkinen KAO, Guyatt G, Akl EA. 2016. Requirements of clinical journals for authors' disclosure of financial and non-financial conflicts of interest: a cross sectional study. PLOS ONE 11(3):e0152301 DOI 10.1371/journal.pone.0152301.
10. Tao DL, Boothby A, McLouth J, Prasad V. 2017. Financial conflicts of interest among hematologist-oncologists on twitter. JAMA Internal Medicine 177(3):425-427 DOI 10.1001/jamainternmed.2016.8467.
11. Tarkang EE, Kweku M, Zotor FB. 2017. Publication practices and responsible authorship: a review article. Journal of Public Health in Africa 8(1):723 DOI 10.4081/jphia.2017.723.
12. Thomas K, Ornstein C. 2018. Top sloan kettering cancer doctor resigns after failing to disclose industry ties. The New York Times. Available at https://www.nytimes.com/2018/09/13/health/ jose-baselga-cancer-memorial-sloan-kettering.html (accessed 20 October 2018).
13. Tibau A, Bedard PL, Srikanthan A, Ethier J-L, Vera-Badillo FE, Templeton AJ, Ocaña A, Seruga B, Barnadas A, Amir E. 2015. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 33(1):100-106 DOI 10.1200/JCO.2014.57.8898.
14. Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. 2018. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncology 4(10):1426 DOI 10.1001/JAMAONCOL.2018.3738.